346 related articles for article (PubMed ID: 25849602)
1. Gleason 6 Prostate Cancer: Translating Biology into Population Health.
Eggener SE; Badani K; Barocas DA; Barrisford GW; Cheng JS; Chin AI; Corcoran A; Epstein JI; George AK; Gupta GN; Hayn MH; Kauffman EC; Lane B; Liss MA; Mirza M; Morgan TM; Moses K; Nepple KG; Preston MA; Rais-Bahrami S; Resnick MJ; Siddiqui MM; Silberstein J; Singer EA; Sonn GA; Sprenkle P; Stratton KL; Taylor J; Tomaszewski J; Tollefson M; Vickers A; White WM; Lowrance WT
J Urol; 2015 Sep; 194(3):626-34. PubMed ID: 25849602
[TBL] [Abstract][Full Text] [Related]
2. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
3. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
4. Contemporary grading for prostate cancer: implications for patient care.
Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
[TBL] [Abstract][Full Text] [Related]
5. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
6. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
8. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
9. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
10. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
Patel HD; Tosoian JJ; Carter HB; Epstein JI
JAMA Oncol; 2018 Jan; 4(1):89-92. PubMed ID: 28715578
[TBL] [Abstract][Full Text] [Related]
11. Defining the threshold for significant versus insignificant prostate cancer.
Van der Kwast TH; Roobol MJ
Nat Rev Urol; 2013 Aug; 10(8):473-82. PubMed ID: 23712205
[TBL] [Abstract][Full Text] [Related]
12. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
13. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.
Wilt TJ
Semin Urol Oncol; 2002 Feb; 20(1):10-7. PubMed ID: 11828353
[TBL] [Abstract][Full Text] [Related]
14. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
[TBL] [Abstract][Full Text] [Related]
15. Do Gleason patterns 3 and 4 prostate cancer represent separate disease states?
Lavery HJ; Droller MJ
J Urol; 2012 Nov; 188(5):1667-75. PubMed ID: 22998919
[TBL] [Abstract][Full Text] [Related]
16. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
Huland H; Graefen M
Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
[TBL] [Abstract][Full Text] [Related]
17. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
18. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]